Abstract
Warfarin reduces effectively the incidence of ischemic stroke in patients with non-valvular atrial fibrillation (AF) but increases the risk of major and intracerebral bleeding. The three new oral anticoagulants (NOAC) dabigatran (110mg bid (D220) and 150mg bid (D300), RE-LY trial), rivaroxaban (20mg od, R20, ROCKET trial), and apixaban (5mg bid, A10, ARISTOTLE trial) showed equivalent or superior efficacy and safety compared to warfarin in these patients. We aimed to analyse the value-based price (Euro) for Germany for these NOACs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
